Publicaciones
-
Tachó-Piñot R, Bashour H, Filipska M, Corral-Vazquez C, Guzman M, Marcos-Fa X, Martinuzzi D, Honner H, Canales Herrerias P, Tejedor Vaquero S, Sáez Gordón A, Perera-Bel J, Domínguez Barragán J, Arcos-Ribas B, de Campos-Mata L, Slabodkin A, Chernigovskaya M, Rodríguez de la Concepción ML, Gutierrez-Marcos J, García-García AP, Nascimento-Osorio A, Pascal M, Yagüe-Ribes J, Juan-Otero M, Arostegui-Gorospe JI, Hijano Esqué R, Sánchez Font A, Ehl S, Grimbacher B, Rizzi M, Dotta L, Chen K, Badolato R, Alsina L, Mehandru S, Cunningham-Rundles C, Carrillo J, Magri G, Greiff V and Cerutti A.
IgD from atypical-like memory B cells and plasma cells targets commensal and environmental antigens.
JOURNAL OF EXPERIMENTAL MEDICINE . 223(5): .
-
Gómez-Andrés D, Munell F, Pascual Pascual SI, Vázquez López M, Cols M, García Campos O, Garrido C, Antonia Grimalt M, Hernandez A, Madruga-Garrido M, Medina J, Molera C, Moreno T, Muñoz Cabello B, Nascimento-Osorio A, Pinillos-Pisón S and Ortez-Gonzalez CI.
Multidisciplinary management of X-linked myotubular myopathy in Spain and Portugal: A case series analysis.
Neurologia . 41(4): 501935-501935.
-
Mendell JR, Muntoni F, McDonald CM, Mercuri EM, Ciafaloni E, Komaki H, Leon-Astudillo C, Nascimento-Osorio A, Proud C, Schara-Schmidt U, Veerapandiyan A, Zaidman CM, Furgerson M, Ding K, Singh P, Potter R, Asher DR, Murphy AP, Reid C, Hooper G, Torre CO, Manfrini M and Rodino-Klapac LR.
Two-Year Outcomes Following Delandistrogene Moxeparvovec Treatment in Ambulatory Patients with Duchenne Muscular Dystrophy: Phase 3 EMBARK Trial
Neurology and Therapy . 15(2): 545-559. Nº de citas: 2
-
Zwingli G, Putananickal N, Schmidt S, Nagy S, Rubino-Nacht D, Schaedelin S, Amthor H, Childs AM, Deconinck N, Horrocks I, Houwen-van Opstal S, Laugel V, Lopez Lobato M, Nascimento-Osorio A, Schara-Schmidt U, Spinty S, von Moers A, Lawrence F, Hafner P, Dorchies OM, Fischer D and Henzi BC.
Safety and efficacy of tamoxifen in patients with duchenne muscular dystrophy: open label extension of TAMDMD trial
NEUROMUSCULAR DISORDERS . 61: 106366-106366.
-
Domínguez-González C, Barba Romero MÁ, Caballero Eraso C, de Las Heras J, Farrero Muñoz E, García-Campos Ó, González M, Grau JM, Hernández-Voth A, Juntas Morales R, León Hernández JC, Ley Martos M, López-Padilla D, Muelas N, Nascimento-Osorio A, Olivé M, Paradas C, Pardo Fernández J, Pascual SI, Pitarch I, Sancho J and Díaz-Manera J.
Recommendations for the diagnosis, treatment, and follow-up of late-onset Pompe disease.
Neurologia . 41(2): 501933-501933.
-
Muntoni, F, Nascimento-Osorio A, Shin, J, Guglieri, M, Stettner, GM, Veerapandiyan, A, Gallo, S, Shi, HL, Gundapaneni, B, Neelakantan, S, Lobello, K, Shen, Q, Levy, D and Mercuri, E.
Safety and efficacy of fordadistrogene movaparvovec in ambulatory participants with Duchenne muscular dystrophy (CIFFREO): a phase 3, double-blind, randomised placebo-controlled study
LANCET NEUROLOGY . 25(3): 245-255. Nº de citas: 1
-
Nafria-Escalera B, Claverol J, Cubells M, Llanos C, Solé L, Sans E, López S, Català-Mora J, Rives-Solà S, Morales-La Madrid A, Pineda M, Garcia-Cazorla A, Nascimento-Osorio A, Morales-Ballús M, Roe D, Fortuny-Guasch C and Phillips B.
Cross-border access to clinical trials: participation of pediatric patients and language inclusion
PEDIATRIC RESEARCH . : .
-
Audhya I, Nacson AB, Gooch K, Basnyat B, Slota C, Martin S, Murphy A, Lansdall CJ, Ciobanu T, Nascimento-Osorio A and Veerapandiyan A.
Caregiver-reported Patient Experiences with Duchenne Muscular Dystrophy: Qualitative In-trial Interviews 1 Year After Delandistrogene Moxeparvovec in the Pivotal EMBARK Trial
Neurology and Therapy . 15(1): 41-60.
-
Nolasco-Tovar GA, Roldan-Molina M, Jamshidi Y, Georvasilis I, Rodríguez RJ, Boostani R, Shoeibi A, Armengol L, Codina-Bergadà A, Karimiani EG, Hernando-Davalillo C, Martorell-Sampol L, Ramírez Almaraz ML, Muchart-Lopez J, Ortez-Gonzalez CI, Nascimento-Osorio A, Urreizti R, Natera-de Benito D and Serrano M.
Expanding Hereditary Spastic Paraplegias Limits: Biallelic SPAST Variants in Cerebral Palsy Mimics
Annals of Clinical and Translational Neurology . 13(1): 108-121.
-
Severa, G, Bastu, S, Borin, GU, Decrouy, X, Codina-Bergadà A, Kefi, K, Periou, B, Nadaj-Pakleza, A, Lannes, B, Sacconi, S, Maurage, CA, Tard, C, Jou-Munoz C, Nascimento-Osorio A, Taglietti, V and Malfatti, E.
Autophagy impairment is associated with enhanced satellite cell activation in muscle biopsies from younger late-onset Pompe disease patients
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY . 85(1): 84-92.